Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Glycom A/S has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 5 distinct examiners working in 3 distinct art units. This structure indicates that while the examiners are all different, they are concentrated within a small number of specialized units, which could lead to consistent policy application across the portfolio.
KRISHNAN, GANAPATHY is the busiest examiner for this company, with 1 busiest examiner pending action. Since there are 5 pending office actions and 5 distinct examiners, each examiner is currently managing exactly one action for the portfolio. This distribution suggests that the company's prosecution efforts are not concentrated under any single individual. The use of 3 distinct art units for 5 actions implies that some examiners are working within the same technical groups, potentially sharing oversight or internal guidelines.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| WHITE, ASHLEY TAYLOR | 1 | 23.8% | +36.7% |
| BRANDSEN, BENJAMIN MICHAEL | 1 | 60.9% | +21.7% |
| KOROTCHKINA, LIOUBOV G | 1 | 29.0% | +64.1% |
| REGA, KYLE THOMAS | 1 | 63.0% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17754400 | SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM FERMENTATION BROTH | KOROTCHKINA, LIOUBOV G | 8d overdue |
| 18262099 | NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (FRED) IN PRODUCTION OF SIALYLATED HMOS | WHITE, ASHLEY TAYLOR | 15d |
| 18808271 | MIXTURE OF HMOs | KRISHNAN, GANAPATHY | — |
| 18255703 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN SUPPORTING MATURATION OR IMPROVEMENT OF SLEEPING PATTERNS | BRANDSEN, BENJAMIN MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17754400 | SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM FERMENTATION BROTH | KOROTCHKINA, LIOUBOV G | 8d overdue |
| 18262099 | NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (FRED) IN PRODUCTION OF SIALYLATED HMOS | WHITE, ASHLEY TAYLOR | 15d |
| 18255703 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN SUPPORTING MATURATION OR IMPROVEMENT OF SLEEPING PATTERNS | BRANDSEN, BENJAMIN MICHAEL | — |
| 17299583 | SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V | REGA, KYLE THOMAS | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1653 | 2 |
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18808271 | MIXTURE OF HMOs | KRISHNAN, GANAPATHY | 1693 | §101§103DP | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18262099 | NEW MAJOR FACILITATOR SUPERFAMILY (MFS) PROTEIN (FRED) IN PRODUCTION OF SIALYLATED HMOS | WHITE, ASHLEY TAYLOR | 1653 | §103 | Final Rejection | 15d | Pending | Jul 19, 2023 |
| 18255703 | HUMAN MILK OLIGOSACCHARIDES FOR USE IN SUPPORTING MATURATION OR IMPROVEMENT OF SLEEPING PATTERNS | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103§112Other | Final Rejection | — | Pending | Jun 02, 2023 |
| 17754400 | SEPARATION OF NEUTRAL OLIGOSACCHARIDES FROM FERMENTATION BROTH | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Final Rejection | 8d overdue | Pending | Mar 31, 2022 |
| 17299583 | SYNTHESIS OF THE FUCOSYLATED OLIGOSACCHARIDE LNFP-V | REGA, KYLE THOMAS | 1636 | §103 | Final Rejection | — | Pending | Jun 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGlycom A/S has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Ganapathy Krishnan has the most, with 1 of Glycom A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
